The neurological burden of cirrhosis: a comprehensive clinical review of mechanisms, diagnosis, and management

Abstract

The neurological burden of liver cirrhosis extends far beyond the classical paradigm of hepatic encephalopathy (HE). This comprehensive clinical review synthesizes the pathophysiology, diagnosis, and contemporary management of the broad spectrum of liver-brain axis complications. Historically, neurological deterioration in these patients has been centered on ammonia toxicity, astrocyte swelling, and neuroinflammation characteristic of HE. However, chronic liver failure and portosystemic shunting also lead to the accumulation of other potent neurotoxins, such as manganese, triggering severe and often irreversible motor syndromes, including acquired hepatocerebral degeneration and hepatic myelopathy. Additionally, peripheral neuropathy and dysautonomia represent profoundly underdiagnosed comorbidities driven by metabolic derangement, toxins, and chronic inflammation. As the disease progresses, systemic instability generates new threats: a precarious hemostatic rebalancing predisposes patients to devastating ischemic and hemorrhagic cerebrovascular complications, challenging the outdated paradigm of “auto-anticoagulation”. Concurrently, cirrhosis-associated immune dysfunction and bacterial translocation facilitate the development of atypical neuroinfections that frequently masquerade as refractory HE, demanding advanced diagnostic tools and prognostic scores like CLIF-SOFA rather than traditional sepsis criteria. Finally, we address neuromotor and circadian disorders-namely restless legs syndrome, debilitating muscle cramps, and insomnia-which drastically deteriorate patients’ daily quality of life. Mitigating this complex neurological morbidity requires a definitive paradigm shift: moving beyond

References

[1] Battle A, Mudd J, Ahlenstiel G, Kalo E. Liver Cirrhosis: Evolving Definitions, and Recent Advances in Diagnosis, Prevention and Management. Livers. 2025; 5: 28.

[2] D’Amico G, Bernardi M, Angeli P. Towards a new definition of decompensated cirrhosis. J Hepatol. 2022; 76: 202-7.

[3] Pearson J, Thomson E. Decompensated liver cirrhosis. Anaest Intens Care M. 2021; 22: 107-12.

[4] Sureka B, Bansal K, Patidar Y, Rajesh S, Mukund A, Arora A. Neurologic Manifestations of Chronic Liver Disease and Liver Cirrhosis. Curr Probl Diagn Radiol. 2015; 44: 449-61.

[5] Shin HW, Park HK. Recent Updates on Acquired Hepatocerebral Degeneration. Tremor Other Hyperkinet Mov (N Y). 2017; 7: 463.

[6] Ferro JM, Viana P, Santos P. Management of Neurologic Manifestations in Patients with Liver Disease. Curr Treat Options Neurol. 2016; 18: 37.

[7] Pinarbasi B, Kaymakoglu S, Matur Z, Akyuz F, Demir K, Besisik F, et al. Are acquired hepatocerebral degeneration and hepatic myelopathy reversible? J Clin Gastroenterol. 2009; 43: 176-81.

[8] Albillos A, Martin-Mateos R, Van der Merwe S, Wiest R, Jalan R, Álvarez-Mon M. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol. 2022; 19: 112-34.

[9] Donovan LM, Kress WL, Strnad LC, Sarwar A, Patwardhan V, Piatkowski G, et al. Low likelihood of intracranial hemorrhage in patients with cirrhosis and altered mental status. Clin Gastroenterol Hepatol. 2015; 13: 165-9.

[10] Rahimi RS, Rockey DC. Overuse of Head Computed Tomography in Cirrhosis With Altered Mental Status. Am J Med Sci. 2016; 351: 459-66.

[11] Fallahzadeh MA, Rahimi RS. Hepatic Encephalopathy: Current and Emerging Treatment Modalities. Clin Gastroenterol Hepatol. 2022; 20: S9-19.

[12] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022; 77: 807-24.

[13] Thabut D, Bouzbib C, Meunier L, Haas M, Weiss N, Louvet A, et al. Diagnosis and management of hepatic encephalopathy: The French recommendations. Liver Int. 2023; 43: 750-62.

[14] Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014; 60: 715-35.

[15] Parikh NS, Basu E, Hwang MJ, Rosenblatt R, VanWagner LB, Lim HI, et al. Management of Stroke in Patients With Chronic Liver Disease: A Practical Review. Stroke. 2023; 54: 2461-71.

[16] Zheng K, Yoshida EM, Tacke F, Li Y, Guo X, Qi X. Risk of Stroke in Liver Cirrhosis: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2020; 54: 96-105.

[17] Xiong J, Xu W, Huang H, Bian J, Wang A, Bai Y, et al. Cirrhosis and risk of stroke: A systematic review and meta-analysis. Atherosclerosis. 2018; 275: 296-303.

[18] Gonzalez JJ, Tapper EB. Muscle cramps in cirrhosis. Clin Liver Dis (Hoboken). 2024; 23: e0116.

[19] Kalia S, Nath P, Pathak M, Anand AC. Treatment of Muscle Cramps in Patients With Cirrhosis of Liver: A Systematic Review. J Clin Exp Hepatol. 2022; 12: 980-92.

[20] Nakanishi H, Kurosaki M, Tsuchiya K, Nakakuki N, Takada H, Matsuda S, et al. L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2015; 13: 1540-3.

[21] Roberts AT, Makar J, Abdelmalak J, Sinclair M, Testro A, Majumdar A. Management of Muscle Cramps in Patients With Cirrhosis: A Systematic Review of Randomised Controlled Trials. Aliment Pharmacol Ther. 2025; 61: 44-64.

[22] Bruyneel M, Sersté T. Sleep disturbances in patients with liver cirrhosis: prevalence, impact, and management challenges. Nat Sci Sleep. 2018; 10: 369-75.

[23] Grønbæk L, Watson H, Vilstrup H, Jepsen P. Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites. United European Gastroenterol J. 2018; 6: 407-12.

[24] Weersink RA, Drenth JPH, Borgsteede SD. Why zolpidem increases the risk of falls and fractures in patients with cirrhosis. JHEP Rep. 2022; 4: 100528.

[25] Elsaid MI, Rustgi VK. Epidemiology of Hepatic Encephalopathy. Clin Liver Dis. 2020; 24: 157-74.

[26] Louissaint J, Deutsch-Link S, Tapper EB. Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy. Clin Gastroenterol Hepatol. 2022; 20: S1-8.

[27] Wijdicks EF. Hepatic Encephalopathy. N Engl J Med. 2016; 375: 1660-70.

[28] Häussinger D, Dhiman RK, Felipo V, Görg B, Jalan R, Kircheis G, et al. Hepatic encephalopathy. Nat Rev Dis Primers. 2022; 8: 43.

[29] Butterworth RF. Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure. J Clin Exp Hepatol. 2015; 5: S96-103.

[30] Liotta EM, Kimberly WT. Cerebral edema and liver disease: Classic perspectives and contemporary hypotheses on mechanism. Neurosci Lett. 2020; 721: 134818.

[31] Häussinger D, Butz M, Schnitzler A, Görg B. Pathomechanisms in hepatic encephalopathy. Biol Chem. 2021; 402: 1087-102.

[32] Isaacks RE, Bender AS, Kim CY, Shi YF, Norenberg MD. Effect of osmolality and anion channel inhibitors on myo-inositol efflux in cultured astrocytes. J Neurosci Res. 1999; 57: 866-71.

[33] Winterdahl M, Abbas Z, Noer O, Thomsen KL, Gras V, Nahimi A, et al. Cerebral water content mapping in cirrhosis patients with and without manifest HE. Metab Brain Dis. 2019; 34: 1071-6.

[34] Cudalbu C, Taylor-Robinson SD. Brain Edema in Chronic Hepatic Encephalopathy. J Clin Exp Hepatol. 2019; 9: 362-82.

[35] Butterworth RF. Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology. Drugs. 2019; 79: 17-21.

[36] Bémeur C, Cudalbu C, Dam G, Thrane AS, Cooper AJ, Rose CF. Brain edema: a valid endpoint for measuring hepatic encephalopathy? Metab Brain Dis. 2016; 31: 1249-58.

[37] Görg B, Schliess F, Häussinger D. Osmotic and oxidative/nitrosative stress in ammonia toxicity and hepatic encephalopathy. Arch Biochem Biophys. 2013; 536: 158-63.

[38] Cichoż-Lach H, Michalak A. Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy. World J Gastroenterol. 2013; 19: 26-34.

[39] Bosoi CR, Rose CF. Brain edema in acute liver failure and chronic liver disease: similarities and differences. Neurochem Int. 2013; 62: 446-57.

[40] Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications: A Review. JAMA. 2023; 329: 1589-602.

[41] Mumdzhiev N, Tenev RV, Radicheva MP. Psychometric hepatic encephalopathy score (PHES)-when, how, why, and why not: a guide for the unfamiliar. Prz Gastroenterol. 2025; 20: 31-5.

[42] Singh J, Sharma BC, Maharshi S, Puri V, Srivastava S. Spectral electroencephalogram in liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy. J Gastroenterol Hepatol. 2016; 31: 1203-9.

[43] Weissenborn K. Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles. Drugs. 2019; 79: 5-9.

[44] Kappus MR, Bajaj JS. Covert hepatic encephalopathy: not as minimal as you might think. Clin Gastroenterol Hepatol. 2012; 10: 1208-19.

[45] Marjot T, Ray DW, Williams FR, Tomlinson JW, Armstrong MJ. Sleep and liver disease: a bidirectional relationship. Lancet Gastroenterol Hepatol. 2021; 6: 850-63.

[46] Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010; 31: 537-47.

[47] Duarte-Rojo A, Allampati S, Thacker LR, Flud CR, Patidar KR, White MB, et al. Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing. Metab Brain Dis. 2019; 34: 289-95.

[48] Newey CR, George P, Sarwal A, So N, Hantus S. Electro-Radiological Observations of Grade III/IV Hepatic Encephalopathy Patients with Seizures. Neurocrit Care. 2018; 28: 97-103.

[49] Halkurike-Jayadevappa VK, Goel A, Paliwal VK, Rai P, Aggarwal R. Liver disease severity is poorly related to the presence of restless leg syndrome in patients with cirrhosis. Neurol India. 2019; 67: 732-7.

[50] Cocito D, Maule S, Paolasso I, Castelli L, Ciaramitaro P, Poglio F, et al. High prevalence of neuropathies in patients with end-stage liver disease. Acta Neurol Scand. 2010; 122: 36-40.

[51] Chen CC, Hsu PW, Lee ST, Chang CN, Wei KC, Wu CT, et al. Brain surgery in patients with liver cirrhosis. J Neurosurg. 2012; 117: 348-53.

[52] Hydes TJ, Meredith P, Schmidt PE, Smith GB, Prytherch DR, Aspinall RJ. National Early Warning Score Accurately Discriminates the Risk of Serious Adverse Events in Patients With Liver Disease. Clin Gastroenterol Hepatol. 2018; 16: 1657-66.e10.

[53] Rashed E, Soldera J. CLIF-SOFA and CLIF-C scores for the prognostication of acute-on-chronic liver failure and acute decompensation of cirrhosis: A systematic review. World J Hepatol. 2022; 14: 2025-43.

[54] Reau N, Bernstein D, Kwo P, Loftus M, Moore A, Saab S. A practical approach to the diagnosis and management of hepatic encephalopathy. Am J Med. 2026; 139: 14-23.e4.

[55] Di Cola S, Nardelli S, Ridola L, Gioia S, Riggio O, Merli M. Ammonia and the Muscle: An Emerging Point of View on Hepatic Encephalopathy. J Clin Med. 2022; 11: 611.

[56] Amariței V, Gheorghita RE, Caliman Sturdza OA. Nutritional Management in Liver Cirrhosis: A Combined Systematic Review and Observational Study. Diseases. 2025; 13: 278.

[57] Calmet F, Martin P, Pearlman M. Nutrition in Patients With Cirrhosis. Gastroenterol Hepatol (N Y). 2019; 15: 248-54.

[58] Vidal-Cevallos P, Chávez-Tapia NC, Uribe M. Current approaches to hepatic encephalopathy. Ann Hepatol. 2022; 27: 100757.

[59] Sharma K, Akre S, Chakole S, Wanjari MB. Hepatic Encephalopathy and Treatment Modalities: A Review Article. Cureus. 2022; 14:e28016.

[60] Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010; 362: 1071-81.

[61] Kircheis G, Lüth S. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy. Drugs. 2019; 79: 23-9.

[62] Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, et al. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013; 143: 1263-8.

[63] Bernardi M, Angeli P, Claria J, Moreau R, Gines P, Jalan R, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut. 2020; 69: 1127-38.

[64] Fernández-Garza LE, González-Torres LA, Estrada-Bellmann I, Cortez-Hernández CA, Fernández-Garza VA, Nomura-Quiroz RP, et al. Revisiting cirrhosis-related parkinsonism: a comprehensive review. Metab Brain Dis. 2026; 41: 112.

[65] Butterworth RF. Parkinsonism in cirrhosis: pathogenesis and current therapeutic options. Metab Brain Dis. 2013; 28: 261-7.

[66] Fernández Carrasco M, Sánchez García O, Plaza Fernández A. Acquired chronic hepatocerebral degeneration (CAHD)-Simulation of parkinsonism, secondary to chronic liver disease. Rev Esp Enferm Dig. 2025; 117: 600-1.

[67] Sahney A, Sharma BC, Jindal A, Anand L, Arora V, Vijayaraghavan R, et al. A double-blind randomized controlled trial to assess efficacy of bromocriptine in cirrhotic patients with hepatic parkinsonism. Liver Int. 2019; 39: 684-93.

[68] Chen P, Chakraborty S, Mukhopadhyay S, Lee E, Paoliello MM, Bowman AB, et al. Manganese homeostasis in the nervous system. J Neurochem. 2015; 134: 601-10.

[69] Peres TV, Parmalee NL, Martinez-Finley EJ, Aschner M. Untangling the Manganese-α-Synuclein Web. Front Neurosci. 2016; 10: 364.

[70] Farina M, Avila DS, da Rocha JB, Aschner M. Metals, oxidative stress and neurodegeneration: a focus on iron, manganese and mercury. Neurochem Int. 2013; 62: 575-94.

[71] Mehkari Z, Mohammed L, Javed M, Althwanay A, Ahsan F, Oliveri F, et al. Manganese, a Likely Cause of ‘Parkinson’s in Cirrhosis’, a Unique Clinical Entity of Acquired Hepatocerebral Degeneration. Cureus. 2020; 12: e10448.

[72] Sidoryk-Wegrzynowicz M, Aschner M. Manganese toxicity in the central nervous system: the glutamine/glutamate-γ-aminobutyric acid cycle. J Intern Med. 2013; 273: 466-77.

[73] Sarkar S, Rokad D, Malovic E, Luo J, Harischandra DS, Jin H, et al. Manganese activates NLRP3 inflammasome signaling and propagates exosomal release of ASC in microglial cells. Sci Signal. 2019; 12: eaat9900.

[74] Harischandra DS, Jin H, Anantharam V, Kanthasamy A, Kanthasamy AG. α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson’s disease. Toxicol Sci. 2015; 143: 454-68.

[75] Xu B, Wu SW, Lu CW, Deng Y, Liu W, Wei YG, et al. Oxidative stress involvement in manganese-induced alpha-synuclein oligomerization in organotypic brain slice cultures. Toxicology. 2013; 305: 71-8.

[76] Xu B, Jin CH, Deng Y, Liu W, Yang TY, Feng S, et al. Alpha-synuclein oligomerization in manganese-induced nerve cell injury in brain slices: a role of NO-mediated S-nitrosylation of protein disulfide isomerase. Mol Neurobiol. 2014; 50: 1098-110.

[77] Burkhard PR, Delavelle J, Du Pasquier R, Spahr L. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol. 2003; 60: 521-8.

[78] Jog MS, Lang AE. Chronic acquired hepatocerebral degeneration: case reports and new insights. Mov Disord. 1995; 10: 714-22.

[79] Mendez MF. Hepatic dementia or acquired hepatocerebral degeneration. J Am Geriatr Soc. 1989; 37: 259-60.

[80] Gleason A, Hayhow B, Walterfang M, Evans A, Mocellin R, Gates P, et al. Neuropsychiatric symptoms as the presenting feature of acquired hepatocerebral degeneration. Aust N Z J Psychiatry. 2014; 48: 959-60.

[81] Maffeo E, Montuschi A, Stura G, Giordana MT. Chronic acquired hepatocerebral degeneration, pallidal T1 MRI hyperintensity and manganese in a series of cirrhotic patients. Neurol Sci. 2014; 35: 523-30.

[82] Sung JH, Kim CY, Yang SO, Khang HS, Cheong HK, Lee JS, et al. Changes in blood manganese concentration and MRI t1 relaxation time during 180 days of stainless steel welding-fume exposure in cynomolgus monkeys. Inhal Toxicol. 2007; 19: 47-55.

[83] Krieger S, Jauss M, Jansen O, Stiehl A, Sauer P, Geissler M, et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. J Hepatol. 1997; 27: 121-6.

[84] Yang HJ, Park SH, Seo M, Weon YC, Kim Y. ¹⁸F-FP-CIT dopamine transporter PET findings in cirrhotic patients with parkinsonism. Neurotoxicology. 2018; 64: 78-84.

[85] Finlayson MH, Superville B. Distribution of cerebral lesions in acquired hepatocerebral degeneration. Brain. 1981; 104: 79-95.

[86] Soffer D, Sherman Y, Tur-Kaspa R, Eid A. Acquired hepatocerebral degeneration in a liver transplant recipient. Acta Neuropathol. 1995; 90: 107-11.

[87] Qavi AH, Hammad S, Rana AI, Salih M, Shah NH, Dar FS, et al. Reversal of acquired hepatocerebral degeneration with living donor liver transplantation. Liver Transpl. 2016; 22: 125-9.

[88] Apetauerova D, Hildebrand P, Scala S, Zani JW, Lipert L, Clark E, et al. A Prospective Study of the Prevalence of Parkinsonism in Patients With Liver Cirrhosis. Hepatol Commun. 2020; 5: 323-33.

[89] Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014; 59: 1144-65.

[90] Hisahara S, Matsushita T, Kitamura M, Mezawa S, Nonaka M, Imai T, et al. Long-term clinical and radiological improvement of chronic acquired hepatocerebral degeneration after obliteration of portosystemic shunt: Report of a case. J Neurol Sci. 2014; 346: 303-6.

[91] Park HK, Kim SM, Choi CG, Lee MC, Chung SJ. Effect of trientine on manganese intoxication in a patient with acquired hepatocerebral degeneration. Mov Disord. 2008; 23: 768-70.

[92] Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 2016; 51: 629-50.

[93] Wang MQ, Liu FY, Duan F. Management of surgical splenorenal shunt-related hepatic myelopathy with endovascular interventional techniques. World J Gastroenterol. 2012; 18: 7104-8.

[94] Cheng J, Jiang SW, Zhou ZS, Sun QL. Hepatic encephalomyelopathy: a complication following liver cirrhosis caused by Budd-Chiari syndrome and HBV. J Infect Dev Ctries. 2014; 8: 551-3.

[95] Koul R, Lal BB, Pamecha V, Sarin S, Alam S. Liver Transplantation Reverses Hepatic Myelopathy in 2 Children With Hepatitis A Infection. Child Neurol Open. 2021; 8: 2329048X20983763.

[96] Xue WH, Liu SR, Xia L, Chai YM, Xu P, Hua ZH, et al. [Analysis of clinical characteristics, prognosis, and influencing factors of hepatic myelopathy]. Zhonghua Yi Xue Za Zhi. 2025; 105: 701-7.

[97] Lynberg M, Kirti I, Saleh N, Naqvi H. Hepatic Myelopathy: A Rare Complication of Chronic Liver Failure Treated Conservatively Without Liver Transplantation. AIM Clin Cases. 2025; 4: e240940.

[98] Kaur J, Jesrani G, Gupta M, Lehl SS. Spastic paraparesis associated with advanced liver cirrhosis: a condition obscure in terms of treatment and prognosis. BMJ Case Rep. 2020; 13:e235090.

[99] Wang LX, Guo L, Guo F, Ren SY, Fei NB, Liu K, et al. Brain white matter fiber tracts involved in post-transjugular intrahepatic portosystemic shunt hepatic myelopathy. Neuroreport. 2017; 28: 1164-9.

[100] Cui LB, Ren S, Xi YB, Zeng LL, Chen G, Liu K, et al. Motor Cortex Mapping in Patients With Hepatic Myelopathy After Transjugular Intrahepatic Portosystemic Shunt. Acad Radiol. 2019; 26: e38-46.

[101] ZIEVE L, MENDELSON DF, GOEPFERT M. Shunt encephalomyelopathy. II. Occurrence of permanent myelopathy. Ann Intern Med. 1960; 53: 53-63.

[102] Mhiri M, Ben Abdelwahed M, Dhiflaoui MA, Ben Dhia R, Gouta N, Jemni I, et al. Hepatic myelopathy neurological complication of chronic liver disease: two case reports. J Med Case Rep. 2024; 18: 281.

[103] Ben Amor S, Saied MZ, Harzallah MS, Benammou S. Hepatic myelopathy with spastic paraparesis: report of two cases and review of the literature. Eur Spine J. 2014; 23 Suppl 2: 167-71.

[104] Utku U, Asil T, Balci K, Uzunca I, Celik Y. Hepatic myelopathy with spastic paraparesis. Clin Neurol Neurosurg. 2005; 107: 514-6.

[105] Kori P, Sahu R, Jaiswal A, Shukla R. Hepatic myelopathy: an unusual neurological complication of chronic liver disease presenting as quadriparesis. BMJ Case Rep. 2013; 2013: bcr2013009078.

[106] Conell-Price J. Neurologic Manifestations of Hepatic and Gastrointestinal Disease. Continuum (Minneap Minn). 2026; 32: 75-104.

[107] Patel DM, Hoch MJ, Mohan SK, Hu R. Hepatic Myelopathy: Case Report of an Unusual MRI Finding. Neurographics. 2018; 8: 204-7.

[108] Nardone R, Buratti T, Oliviero A, Lochmann A, Tezzon F. Corticospinal involvement in patients with a portosystemic shunt due to liver cirrhosis: a MEP study. J Neurol. 2006; 253: 81-5.

[109] Chang CY, Liu C, Duan FF, Zhai H, Song SS, Yang S. Spontaneous remission of hepatic myelopathy in a patient with alcoholic cirrhosis: A case report. World J Clin Cases. 2022; 10: 11172-7.

[110] Liu F, Deng J, Li Z, Huang Z. Hepatic myelopathy improved by embolization of spontaneous portosystemic shunt and partial splenic artery embolization-Literature review. Rev Esp Enferm Dig. 2026; 118: 119-20.

[111] Philips CA, Kumar L, Augustine P. Partial splenic artery embolization for severe hepatic myelopathy in cirrhosis. Hepatology. 2018; 67: 1169-71.

[112] Sun L, Li J, Lan LL, Li XA. The effect of fecal microbiota transplantation on Hepatic myelopathy: A case report. Medicine (Baltimore). 2019; 98: e16430.

[113] Li J, Wan S, Wen F, Li Q, Cui Y, Lu Z, et al. Liver Transplantation Reverses Hepatic Myelopathy in the Decompensated Phase of Cirrhosis: Case Report and Literature Review. J Clin Transl Hepatol. 2024; 12: 436-42.

[114] Knill-Jones RP, Goodwill CJ, Dayan AD, Williams R. Peripheral neuropathy in chronic liver disease: clinical, electrodiagnostic, and nerve biopsy findings. J Neurol Neurosurg Psychiatry. 1972; 35: 22-30.

[115] Chaudhry V, Corse AM, O’Brian R, Cornblath DR, Klein AS, Thuluvath PJ. Autonomic and peripheral (sensorimotor) neuropathy in chronic liver disease: a clinical and electrophysiologic study. Hepatology. 1999; 29: 1698-703.

[116] Dudek I, Hajduga D, Sieńko C, et al. Alcohol-Induced Neuropathy in Chronic Alcoholism: Causes, Pathophysiology, Diagnosis, and Treatment Options. Curr Pathobiol Rep. 2020; 8: 87-97.

[117] Julian T, Glascow N, Syeed R, Zis P. Alcohol-related peripheral neuropathy: a systematic review and meta-analysis. J Neurol. 2019; 266: 2907-19.

[118] Mathis S, Magy L, Le Masson G, Richard L, Soulages A, Solé G, et al. Value of nerve biopsy in the management of peripheral neuropathies. Expert Rev Neurother. 2018; 18: 589-602.

[119] Murphy SL, Tapper EB, Blackwood J, Richardson JK. Why Do Individuals with Cirrhosis Fall? A Mechanistic Model for Fall Assessment, Treatment, and Research. Dig Dis Sci. 2019; 64: 316-23.

[120] Bashir A, Ahmad F, Ali khan S, Subhan Z, Jabeen Shah S, Ali K, et al. Comparing Frequency of Cardiovascular Autonomic Neuropathy in Diabetic Cirrhotic with Non-Diabetic Cirrhotic Patients. Pak BioMed J. 2022; 5: 95-102.

[121] Ângelo I, Lopes Ferreira J, Peixoto J, Fernandes M. Acrocyanosis A Manifestation of Autonomic Dysfunction in Chronic Liver Disease-Case Report. J Gast Hepa Rep. 2022; 3: 1-2.

[122] Neonaki A, Lekakis V, Cholongitas E. The predictive role of autonomic neuropathy in pre- and post-liver transplantation outcomes: a systematic review and meta-analysis. Ann Gastroenterol. 2024; 37: 588-601.

[123] Bajaj BK, Agarwal MP, Ram BK. Autonomic neuropathy in patients with hepatic cirrhosis. Postgrad Med J. 2003; 79: 408-11.

[124] Di Stefano C, Milazzo V, Milan A, Veglio F, Maule S. The role of autonomic dysfunction in cirrhotic patients before and after liver transplantation. Review of the literature. Liver Int. 2016; 36: 1081-9.

[125] Gabr RM, El Salmawy DA, Basheer MA, Khairy M, Elkholy SH. Relation between the severity of liver cirrhosis and neurological symptoms, nerve conduction study results, and motor unit number estimation. J Viral Hepat. 2021; 28: 1312-8.

[126] Gentile S, Marmo R, Peduto A, Montella F, Coltorti M. Autonomic neuropathy in liver cirrhosis: relationship with alcoholic aetiology and severity of the disease. Ital J Gastroenterol. 1994; 26: 53-8.

[127] Keresztes K, Istenes I, Folhoffer A, Lakatos PL, Horvath A, Csak T, et al. Autonomic and sensory nerve dysfunction in primary biliary cirrhosis. World J Gastroenterol. 2004; 10: 3039-43.

[128] Holman A, Parikh N, Clauw DJ, Williams DA, Tapper EB. Contemporary management of pain in cirrhosis: Toward precision therapy for pain. Hepatology. 2023; 77: 290-304.

[129] Pérez-Peña J, Rincón D, Bañares R, Olmedilla L, Garutti I, Grigorov I, et al. Autonomic neuropathy in end-stage cirrhotic patients and evolution after liver transplantation. Transplant Proc. 2003; 35: 1834-5.

[130] Lee TH. Intracerebral Hemorrhage. Cerebrovasc Dis Extra. 2025; 15: 1-8.

[131] Huang HH, Lin HH, Shih YL, Chen PJ, Chang WK, Chu HC, et al. Spontaneous intracranial hemorrhage in cirrhotic patients. Clin Neurol Neurosurg. 2008; 110: 253-8.

[132] Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016; 8: 39-50.

[133] Bos S, van den Boom B, Kamphuisen PW, Adelmeijer J, Blokzijl H, Schreuder T, et al. Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis. Thromb Haemost. 2019; 119: 246-53.

[134] Yi H, Zhang Y, Zhou Z, Sun W, Wang Y, Tao W, et al. Diagnostic Performance of Noninvasive Tests for Identifying Advanced Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease With Mixed Etiologies. Endocr Pract. 2025; 31: 995-1001.

[135] Hoya K, Tanaka Y, Uchida T, Takano I, Nagaishi M, Kowata K, et al. Intracerebral hemorrhage in patients with chronic liver disease. Neurol Med Chir (Tokyo). 2012; 52: 181-5.

[136] Lin YT, Cheng YK, Lin CL, Wang IK. Increased risk of subdural hematoma in patients with liver cirrhosis. QJM. 2017; 110: 815-20.

[137] Kolcun JPG, Gernsback JE, Richardson AM, Jagid JR. Flow, Liver, Flow: A Retrospective Analysis of the Interplay of Liver Disease and Coagulopathy in Chronic Subdural Hematoma. World Neurosurg. 2017; 102: 246-52.

[138] Lee JM, Park JC, Kim JH. Retrospective Analysis of Risk Factors for Recurrent Chronic Subdural Hematoma. The Nerve. 2016; 2: 54-8.

[139] Shin HJ, Ha SW, Kim SW. Delayed Onset Acute Subdural Hematoma after Burr Hole Drainage in a Patient with Chronic Subdural Hematoma and Liver Cirrhosis. Korean J Neurotrauma. 2021; 17: 156-61.

[140] Kuo L, Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, et al. Liver Cirrhosis in Patients With Atrial Fibrillation: Would Oral Anticoagulation Have a Net Clinical Benefit for Stroke Prevention? J Am Heart Assoc. 2017; 6: e005307.

[141] Lai HC, Chien WC, Chung CH, Lee WL, Wu TJ, Wang KY, et al. Atrial fibrillation, liver disease, antithrombotics and risk of cerebrovascular events: A population-based cohort study. Int J Cardiol. 2016; 223: 829-37.

[142] Wu HY, Lin CS, Yeh CC, Hu CJ, Shih CC, Cherng YG, et al. Cirrhosis patients’ stroke risks and adverse outcomes: Two nationwide studies. Atherosclerosis. 2017; 263: 29-35.

[143] Parikh NS, Merkler AE, Schneider Y, Navi BB, Kamel H. Discharge Disposition After Stroke in Patients With Liver Disease. Stroke. 2017; 48: 476-8.

[144] Small C, Attridge RL, Franco-Martinez C, Donnelly J, Barthol C. Prothrombin Complex Concentrate Use in Intracranial Hemorrhage Patients With Cirrhosis Not on Prior Anticoagulation. J Intensive Care Med. 2022; 37: 633-40.

[145] Fernández J, Piano S, Bartoletti M, Wey EQ. Management of bacterial and fungal infections in cirrhosis: The MDRO challenge. J Hepatol. 2021; 75 Suppl 1: S101-17.

[146] Bajaj JS, Kamath PS, Reddy KR. The Evolving Challenge of Infections in Cirrhosis. N Engl J Med. 2021; 384: 2317-30.

[147] Piano S, Bunchorntavakul C, Marciano S, Reddy KR. Infections in cirrhosis. Lancet Gastroenterol Hepatol. 2024; 9: 745-57.

[148] Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014; 61: 1385-96.

[149] Campbell KA, Trivedi HD, Chopra S. Infections in Cirrhosis: A Guide for the Clinician. Am J Med. 2021; 134: 727-34.

[150] Ekpanyapong S, Reddy KR. Infections in Cirrhosis. Curr Treat Options Gastroenterol. 2019; 17: 254-70.

[151] Cabellos C, Viladrich PF, Ariza J, Maiques JM, Verdaguer R, Gudiol F. Community-acquired bacterial meningitis in cirrhotic patients. Clin Microbiol Infect. 2008; 14: 35-40.

[152] Sawale VM, Lahiri D, Dubey S, Sarkar N. Multiple cerebral abscesses in decompensated cirrhosis of liver as a mimicker of hepatic encephalopathy: A case report. Int J Clin Res. 2018; 4: 304-6.

[153] Roy A, Verma N, Ahuja CK. Intracranial invasive mycosis mimicking hepatic encephalopathy in a patient with cirrhosis. BMJ Case Rep. 2019; 12:e231548.

[154] Ting PS, Agarwalla A, Woreta TA. A Mimic of Hepatic Encephalopathy: Two Cases of Cryptococcal Meningitis in North America. J Clin Transl Hepatol. 2019; 7: 191-3.

[155] Chen YC, Hung TH, Tseng KC, Tseng CW, Hsieh YH, Tsai CC, et al. Increased occurrence of brain abscesses in cirrhotic patients: A population-based 3-year follow-up study. Turk J Gastroenterol. 2017; 28: 342-6.

[156] Pagliano P, Boccia G, De Caro F, Esposito S. Bacterial meningitis complicating the course of liver cirrhosis. Infection. 2017; 45: 795-800.

[157] Umemoto D, Nishioka H. Bacterial Meningitis Associated With Spontaneous Bacterial Peritonitis Caused by Escherichia coli in a Patient With Alcoholic Liver Cirrhosis. Cureus. 2025; 17:e77937.

[158] Laviv Y, Ben-Daviv U, Vated M, Rappaport ZH. Brain abscess following endoscopic ligation of esophageal varicose veins. Acta Neurochir (Wien). 2010; 152: 733-4.

[159] Sevastianos VA, Dourakis SP. Pathogenesis, diagnosis and therapy of Infections complicating patients with chronic liver disease. Ann Gastroenterol. 2003; 16: 300-15.

[160] Flores-Perez RO, Villarreal-Villarreal CD, Garza JAC, Galarza-Delgado DA. Supratentorial Listeria monocytogenes Brain Abscess in a Patient with Liver Cirrhosis. Ann Indian Acad Neurol. 2020; 23: 107-9.

[161] Suh HJ, Choe PG, Song KH, Park WB, Bang JH, Kim ES, et al. Prevalence of cryptococcal antigenemia in hospitalized patients with liver cirrhosis. Med Mycol. 2020; 58: 207-10.

[162] Chuang YM, Ho YC, Chang HT, Yu CJ, Yang PC, Hsueh PR. Disseminated cryptococcosis in HIV-uninfected patients. Eur J Clin Microbiol Infect Dis. 2008; 27: 307-10.

[163] Yamahiro A, Lau KH, Peaper DR, Villanueva M. Meningitis Caused by Candida Dubliniensis in a Patient with Cirrhosis: A Case Report and Review of the Literature. Mycopathologia. 2016; 181: 589-93.

[164] Tang HJ, Liu WL, Chang TC, Li MC, Ko WC, Wu CJ, et al. Multiple Brain Abscesses Due to Aspergillus Fumigatus in a Patient With Liver Cirrhosis: A Case Report. Medicine (Baltimore). 2016; 95: e2813.

[165] Inaba T, Minami K, Ishioka H, Sekiguchi K, Watanabe A, Hatakeyama S. Isolated brain abscess caused by Aspergillus tubingensis in a patient with alcoholic liver cirrhosis. J Infect Chemother. 2025; 31: 102691.

[166] Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017; 66: 1727-38.

[167] Plotogea OM, Ilie M, Bungau S, Chiotoroiu AL, Stanescu AMA, Diaconu CC. Comprehensive Overview of Sleep Disorders in Patients with Chronic Liver Disease. Brain Sci. 2021; 11: 142.

[168] Montagnese S, De Pittà C, De Rui M, Corrias M, Turco M, Merkel C, et al. Sleep-wake abnormalities in patients with cirrhosis. Hepatology. 2014; 59: 705-12.

[169] Nishikawa H, Yoh K, Enomoto H, Iwata Y, Nishimura T, Nishiguchi S, et al. Frailty and Sleep Disorder in Chronic Liver Diseases. Life (Basel). 2020; 10: 137.

[170] Formentin C, Garrido M, Montagnese S. Assessment and Management of Sleep Disturbance in Cirrhosis. Curr Hepatol Rep. 2018; 17: 52-69.

[171] Gencdal G, Gunsar F, Meral CE, Salman E, Gürsel B, Oruç N, et al. Sleep disorders in cirrhotics; how can we detect? Liver Int. 2014; 34: 1192-7.

[172] Gupta R, Gupta R, Kumar N, Rawat VS, Ulfberg J, Allen RP. Restless legs syndrome among subjects having chronic liver disease: A systematic review and meta-analysis. Sleep Med Rev. 2021; 58: 101463.

[173] Akbar K, Iqbal R, Iqbal J, Akhtar MS, Abdullah M. Restless Leg Syndrome and Liver Cirrhosis: is it common? J Sheikh Zayed Med Coll. 2019; 10: 1638-40.

[174] Lin D, Ding J, Liu JY, He YF, Dai Z, Chen CZ, et al. Decreased serum hepcidin concentration correlates with brain iron deposition in patients with HBV-related cirrhosis. PLoS One. 2013; 8: e65551.

[175] Bose S, Jacob S. Restless leg syndrome in patients with liver cirrhosis: Waiting for the shoe to drop. Neurol India. 2019; 67: 657-9.

[176] Goel A, Jat SL, Sasi A, Paliwal VK, Aggarwal R. Prevalence, severity, and impact on quality of life of restless leg syndrome in patients with liver cirrhosis in India. Indian J Gastroenterol. 2016; 35: 216-21.

[177] Moretti R, Caruso P, Tecchiolli M, Gazzin S, Tiribelli C. Management of restless legs syndrome in chronic liver disease: A challenge for the correct diagnosis and therapy. World J Hepatol. 2018; 10: 379-87.

[178] Chatrath H, Liangpunsakul S, Ghabril M, Otte J, Chalasani N, Vuppalanchi R. Prevalence and morbidity associated with muscle cramps in patients with cirrhosis. Am J Med. 2012; 125: 1019-25.

[179] Tapper EB, Salim N, Baki J, Zhao Z, Sundaram V, Patwardhan V, et al. Pickle Juice Intervention for Cirrhotic Cramps Reduction: The PICCLES Randomized Controlled Trial. Am J Gastroenterol. 2022; 117: 895-901.

[180] Miller KC, Mack GW, Knight KL, Hopkins JT, Draper DO, Fields PJ, et al. Reflex inhibition of electrically induced muscle cramps in hypohydrated humans. Med Sci Sports Exerc. 2010; 42: 953-61.